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AbstrACt
Introduction Amyotrophic lateral sclerosis (ALS) is a 
fatal progressive neurological disorder characterised by 
a selective degeneration of motor neurons (MNs). Stem 
cell transplantation is considered as a promising strategy 
in neurological disorders therapy and the possibility 
of inducing bone marrow cells (BMCs) to circulate in 
the peripheral blood is suggested to investigate stem 
cells migration in degenerated ALS nerve tissues where 
potentially repair MN damage. Granulocyte- colony 
stimulating factor (G- CSF) is a growth factor which 
stimulates haematopoietic progenitor cells, mobilises 
BMCs into injured brain and it is itself a neurotrophic factor 
for MN. G- CSF safety in humans has been demonstrated 
and many observations suggest that it may affect neural 
cells. Therefore, we decided to use G- CSF to mobilise 
BMCs into the peripheral circulation in patients with ALS, 
planning a clinical trial to evaluate the effect of G- CSF 
administration in ALS patients compared with placebo.
Methods and analysis STEMALS- II is a phase II 
multicentre, randomised double- blind, placebo- controlled, 
parallel group clinical trial on G- CSF (filgrastim) and 
mannitol in ALS patients. Specifically, we investigate 
safety, tolerability and efficacy of four repeated courses of 
intravenous G- CSF and mannitol administered in 76 ALS 
patients in comparison with placebo (indistinguishable 
glucose solution 5%). We determine increase of G- CSF 
levels in serum and cerebrospinal fluid as CD34+ cells 
and leucocyte count after treatment; reduction in ALS 
Functional Rating Scale- Revised Score, forced vital 
capacity, Scale for Testing Muscle Strength Score and 
quality of life; the adverse events/reactions during the 
treatment; changes in neuroinflammation biomarkers 
before and after treatment.
Ethics and dissemination The study protocol was 
approved by the Ethics Committee of Azienda Ospedaliera 
Universitaria ‘Città della Salute e della Scienza’, Torino, 
Italy. Results will be presented during scientific symposia 
or published in scientific journals.
trial registration number Eudract 2014-002228-28.
IntroduCtIon
Amyotrophic lateral sclerosis (ALS) is a fatal 
severe progressive neurological disorder char-
acterised by a selective degeneration of spinal, 
bulbar and cortical motor neurons (MNs). The 
mean annual ALS incidence rate is 3/100 000 
population.1 The disease includes a sporadic 
form (85%–90% of cases) and familial vari-
ants (10%–15% of cases). Several mechanisms 
have been proposed to explain the progressive 
degeneration of MN, such as oxidative stress, 
neurofilament damage, mitochondrial alter-
ations, glutamate- induced excitotoxicity and 
hypoxia response alteration.
strengths and limitations of this study
 ► We planned a phase II multicentre, randomised 
double- blind, placebo- controlled, parallel group clin-
ical trial on granulocyte- colony stimulating factor (G- 
CSF) and mannitol in amyotrophic lateral sclerosis 
(ALS) patients.
 ► Safety, tolerability and efficacy of G- CSF treatment 
versus placebo are carefully evaluated.
 ► Chemokines and cytokines involved in inflammatory 
biochemical changes are also assessed and cor-
related with demographic and clinical parameters.
 ► The mass of biological data longitudinally collected 
could lead to important information on the trend of 
neuroinflammation in ALS.
 ► Since nutritional and respiratory status may influ-
ence the progression and survival of ALS, the pro-
tocol requires a homogeneous approach to maintain 
respiratory function and nutritional status.
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The goals of ALS therapy are to find treatments that 
can reduce or block neuronal loss and/or to reconstruct 
damaged neuronal circuits. In the past, some experi-
mental drugs showed to delay ALS progression in preclin-
ical animal models but failed in human clinical trials or 
are still in phase I–III trials.2
Currently, the approved therapy for ALS is riluzole, an 
inhibitor of neuronal glutamate release, which prolongs 
survival by 9%.3 Lately, the antioxidant drug edaravone 
has been shown to decrease, although slightly, ALS 
progression measured with the ALS Functional Rating 
Scale- Revised (ALS- FRS- R) Score during early stages and 
has been approved in Japan, South Korea and USA.4
Recently, stem cell transplantation has been suggested 
as a promising strategy in neurological disorders therapy.5 
In addition to offer a possible treatment for patients with 
ALS, it is always necessary to keep careful surveillance on 
the possible side effects, linked to procedures that involve 
delicate steps, such as collection, in vitro manipulation 
and reinfusion of bone marrow cells (BMCs).
The possibility of inducing medullary cells to leave the 
osteomedullary environment and circulate in the periph-
eral blood has long been known. This phenomenon, known 
as ‘mobilisation’, occurs after administration of chemo-
therapy and/or cytokines.6 7 BMCs mobilisation procedure 
has been used for many years in bone marrow transplan-
tation treatments for haematological diseases and involves 
the transit of very immature medullary elements in the 
peripheral bloodstream.8 The recirculation phenomena in 
the peripheral blood of plentiful quantities of BMCs can be 
exploited to try to induce stem cells to migrate and localise 
in damaged areas of non- haematopoietic tissues. In partic-
ular, cytokine- induced BMCs mobilisation could be used in 
an attempt to repair the degenerated areas of nerve tissues 
in ALS. In this regard, it should be remembered that circu-
lating BMCs are able to reach the central nervous system 
(CNS) through the blood–brain barrier (BBB).
A BMCs mobilisation procedure could therefore favour 
the stem cells passage into the nervous tissue. Here, BMCs 
could replace degenerate neurons, through transdiffer-
entiation and reconstruction of functional circuits. Alter-
natively, BMCs could differentiate into glial or microglial 
cells that preserve the MNs still present at spinal and 
cortex level. Anyhow, the advantage of this approach is 
represented by the extent to which the BMCs can reach 
different levels of the disease, that is, cervical and lumbar 
spinal cord, medulla oblongata and pons, motor cortex.
Granulocyte- colony stimulating factor (G- CSF) is a 
growth factor which stimulates proliferation, differentia-
tion and survival of haematopoietic progenitor cells.9 It 
is being used extensively in clinical practice to accelerate 
recovery of patients from neutropenia after cytotoxic 
therapy and on healthy subjects as bone marrow donors 
to mobilise and collect cells for transplantation.10
G- CSF induces a transient mobilisation of haemato-
poietic progenitor cells from bone marrow to periph-
eral blood and mobilises, among others, a population 
of CD34+ haematopoietic stem cells. G- CSF has also 
been shown to mobilise BMCs into the injured brain 
improving neural plasticity.11 12 Some studies have shown 
the potential use of osteomedullary derivation cells, in 
particular of the most immature stem cells, in order to 
repair CNS damage such as those found in MNs of ALS 
patients.13 14 In superoxide dismutase 1 transgenic ALS 
mice models, this approach with BMCs has been shown 
to modify the tissue micro- environment of the nervous 
system generating microglia and glial cells,15–17 slowing 
disease progression and prolonging survival.18 More-
over, in cerebrospinal fluid (CSF) and blood of patients 
before/after the treatment with G- CSF and placebo, 
relevant information about the course of ALS may be 
obtained by the assessment of chemoattractant protein-1 
(MCP-1), interleukin-17 (IL-17), IP10 (CXCL10) and 
NADPH oxidase 2 (NOX2). MCP-1, IL-17 and CXCL10 
are chemokines and cytokines involved in inflamma-
tory biochemical changes,19 20 while NOX2 is the main 
reactive oxygen species (ROS)- producing enzyme, that 
controls key neuronal functions and neuroinflamma-
tory processes. NOX2 inappropriate activation has been 
hypothesised to be damaging in neurodegenerative 
disorders.21
Furthermore, there are also indications that G- CSF is by 
itself a neurotrophic factor for MN,12 and it is thought to 
exert neuroprotective actions through the inhibition of 
apoptosis and inflammation and the stimulation of neuro-
genesis. The direct neuroprotective effect of G- CSF has 
been demonstrated in preclinical models of stroke,11 22 
Parkinson’s disease23 and ALS.24 25
G- CSF goes through the intact BBB, allowing peripheral 
delivery of this protein for the treatment of neurological 
conditions.24 26 This molecule has a strong anti- apoptotic 
effect on neurons through two cellular pathways: (a) acti-
vation of STAT3, ERK1/2 and ERK5, recently implicated 
as factors favouring neuronal survival,27 28 and (b) activa-
tion of PI3K/Akt, a kinase with a powerful regulatory role 
on neuronal survival.29 Furthermore, the G- CSF would 
appear to perform neuroprotective action in mice with 
familial ALS, stimulating the recruitment of microglia 
in the damaged areas.30 The receptor (G- CSF- R) is 
expressed on CNS neurons and glia and its expression 
is induced by different pathogenic noxae.31 32 G- CSF- R is 
present on adult stem cells and induces their differentia-
tion in neurons. It also plays a role as a factor involved in 
the plasticity of the vasculature.9
In the spinal cord, G- CSF has been found expressed 
in reactive astrocytes of eight cases of ALS but not in 
six non- neurological controls, whereas in ALS cases the 
expression of G- CSF- R was significantly reduced in spinal 
motoneurons.33
The downregulation of the G- CSF- R could therefore 
play a role in the pathogenesis of ALS.
Based on this, we planned a double- blind, placebo- 
controlled, parallel group multicentre clinical trial 
to determine whether the treatment with G- CSF and 
mannitol is safe and significantly slows down the rate of 
progression of ALS.
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Figure 1 Design of STEMALS- II study. G- CSF, granulocyte- 
colony stimulating factor.
MEthods And AnAlysIs
objectives
The main objectives of the study are:
 ► To evaluate the safety and tolerability of G- CSF treat-
ment in patients with ALS.
 ► To evaluate the efficacy of G- CSF treatment versus 
placebo in patients with ALS.
 ► To evaluate the changes in CSF/blood inflamma-
tory parameters (CD34+ cells and leucocyte count, 
chemokines, cytokines, NOX2 activity) in patients 
treated with G- CSF compared with those treated with 
placebo.
study design
The acronym of the study is STEMALS- II.
STEMALS- II is a multicentre, phase II randomised, 
double- blind, placebo- controlled, parallel group, 
no- profit clinical trial on G- CSF (filgrastim) intravenous 
treatment in ALS patients.
The design of the study is reported in figure 1.
The expected duration of the study for each patient is 
maximum 76 weeks: a screening period (up to 4 weeks), 
48 weeks of treatment and 24 weeks of follow- up.
In particular, our aim is to evaluate safety, tolerability 
and efficacy of four repeated courses of G- CSF and 
mannitol administered intravenously at 3- month inter-
vals in 76 patients with ALS, assessing the clinical disease 
progression during the 48 weeks of BMCs mobilisation 
cycles and a subsequent 24 weeks of follow- up period.
We determine:
 ► The increase of G- CSF levels in serum and CSF after 
treatment, as CD34+ cells and leucocyte count.
 ► If a significant reduction has occurred in mean 
decrease in ALS- FRS- R Score, forced vital capacity 
(FVC), Scale for Testing Muscle Strength (MRC) 
Score and quality of life (QoL, measured with McGill 
QoL Questionnaire).
 ► The adverse events (AEs)/reactions that may occur in 
patients treated with drug and placebo, and if they are 
transitory.
 ► The changes in chemokines/cytokines levels and 
NOX2 activity in CSF and blood as an in- depth study 
in case of positive response to the treatment.
Since nutritional and respiratory status may influence 
the progression and survival of ALS, the protocol requires 
a homogeneous approach to maintain respiratory func-
tion and nutritional status, through researchers’ explicit 
adhesion to the European Federation of Neurological 
Societies (EFSN) guidelines.34
Participating centres
The study is performed in seven Italian ALS centres with 
haematological laboratories and with experience in the 
use of G- CSF:
 ► Torino (Promoter and Coordinating Centre)—
CRESLA (ALS Regional Expert Centre)—Neurology 
2, ‘Rita Levi Montalcini’ Department of Neurosci-
ence, University of Turin and ‘Azienda Ospedaliero 
Universitaria (AOU) Città della Salute e della Scienza’ 
of Turin.
 ► Milano—NEMO (Neuromuscular Omnicentre) Clin-
ical Center, Serena Onlus Foundation.
 ► Genova—Neurological Clinic I—IRCCS AOU San 
Martino IST Genova.
 ► Novara—ALS Regional Expert Centre, Neurological 
Clinic AOU Maggiore della Carità.
 ► Modena—Operating Unit Neurology, New Civil 
Hospital S. Agostino- Estense of Modena, University of 
Modena and Reggio Emilia.
 ► Palermo—Regional Reference Centre for Motor 
Neuron Diseases- ALS, Department of Emergencies, 
Urgencies and Neurosciences, AOU Policlinic ‘P 
Giaccone’.
 ► Bari—University Hospital Consortium Polyclinic of 
Bari ‘Aldo Moro’—Department of Basic Medical 
Sciences, Neuroscience and Sensory Organs.
Each centre is expected:
 ► To randomise at least four patients fulfilling including 
and excluding criteria in a period of 48 weeks 
(including 4 weeks of screening).
 ► To administer the treatment for the 48 weeks planned 
and perform the follow- up visits.
 ► To provide one principal investigator (PI) (treating 
neurologist), not aware of treatment arm and of 
haematological values (to ensure the ‘double blind’ 
of the study), in order to evaluate inclusion and 
exclusion criteria, provide detailed information on all 
aspects of the trial, obtain signed informed consent, 
administer the treatment and evaluate the end- points.
 ► To provide a laboratory physician/biologist able to 
obtain (always in blind of treatment) the haematolog-
ical values within 2 hours after blood collection and 
send the results by mail to the coordinating centre; 
the same must also verify the carrying out of the 
other tests, in particular the monitoring of circulating 
CD34+ cells.
 ► To evaluate the FVC in a sitting position.
 ► To formally adhere to the EFSN guidelines for the 
management of patients, with particular regard to 
respiratory support and nutrition.
 ► To manage with its own pharmacy the methods of 
provision and management of the drug/placebo and 
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Table 1 Inclusion and exclusion criteria for STEMALS- II trial
Inclusion criteria Exclusion criteria
a. Patients diagnosed with definite, 
probable or probable laboratory- 
supported amyotrophic lateral sclerosis 
according to the EI Escorial revised 
criteria.41
b. Age between 20 and 75 years old.
c. Disease duration from symptoms onset 
≤24 months at the screening visit.
d. Forced vital capacity ≥65% of 
predicted normal value.
e. Documented disease progression in 
the last 3 months.
f. Patients must understand and adhere 
to the study protocol and provide a 
written informed consent.
g. Use of riluzole with a stabilised dose of 
50 mg two times per day for at least 4 
weeks or no use throughout the study.
h. Negative pregnancy test and effective 
contraception for all the duration of the 
study for premenopausal women.
a. Previous poliomyelitis.
b. Other motor neuron diseases (progressive bulbar paralysis, progressive 
muscular atrophy, primary lateral sclerosis).
c. Clinical involvement of other neurological systems (sensory, extrapyramidal, 
oculomotor, cerebellar, vegetative).
d. Severe internal clinical conditions, such as cardiovascular disease, uncontrolled 
arterial hypertension, renal or hepatic failure, dysthyroidism, adult respiratory 
suffering syndrome, sickle cell anaemia.
e. Hypersensitivity to filgrastim, paracetamol or propacetamol hydrochloride (pro- 
drug of paracetamol), mannitol or excipients.
f. Current or past malignancy, except cutaneous neoplasia different from 
melanoma and in situ carcinoma of the cervix.
g. Severe congenital neutropenia (Kostman’s syndrome) with cytogenetic 
abnormalities.
h. Patients with rare hereditary problems of fructose intolerance.
i. Current or past malignant myeloproliferative diseases, secondary polyglobulia, 
splenomegaly with diameter >14 cm, confirmed thrombophilic status.
j. Presence of percutaneous gastrostomy or score ˂2 at the swallowing item of 
the Amyotrophic Lateral Sclerosis Functional Rating Scale- Revised (ALS- FRS- R) 
Score at the recruitment.
k. Presence of non- invasive ventilation at the recruitment (score 4 at item 12 of the 
ALS- FRS- R Score) or tracheotomy.
l. Participation in clinical trial in the 12 weeks before recruitment.
m. Poor compliance with previous treatments.
n. Drug addiction, alcoholism or psychiatric disorders.
o. Pregnant or breastfeed women.
verify to provide all the material necessary for the 
conduct of the study in accordance with the protocol.
Patients
Subjects eligible for the study are adult individuals of 
both sexes, diagnosed with both spinal and bulbar onset 
ALS. All patients must adhere to inclusion and exclusion 
criteria reported in table 1.
randomisation
All eligible patients are randomised to receive G- CSF or 
matching placebo, with 1:1 allocation in two groups of 
38 subjects each. They receive a unique identification 
number at screening visit when signing the informed 
consent. A block stratified randomisation model was used 
with small block size, with stratification for type of onset; 
one- half of the patients in each block are assigned to each 
treatment through random allocation. The randomisa-
tion procedure involved the generation of two lists, one 
for patients with bulbar onset and one for patients with 
spinal onset. Cases with only bulbar signs or symptoms in 
the first 3 months of diagnosis, with subsequent appear-
ance of spinal signs, are considered bulbar- onset ALS. All 
others cases are considered spinal- onset ALS. The rando-
misation lists are informatically generated and are avail-
able on the www. randomization. com site. Patients should 
be randomised and treatment initiated within 4 weeks of 
screening visit (V1).
treatment
Patients are treated in hospital during each cycle of 
G- CSF/placebo administration. Filgrastim (Tevagrastim, 
kindly provided by Teva, Italy) is a recombinant human 
G- CSF whose biological activity is very similar to that of 
endogenous G- CSF. Filgrastim or the matching placebo 
(indistinguishable glucose solution 5%) are administered 
intravenously at a dose of 5 µg/kg two times per day for 
four consecutive days (one cycle). Each course is repeated 
after 12 weeks (times 0, 12, 24 and 36 weeks), for a total of 
four cycles of treatment (48 weeks).
Administration should be as provided in the Summary 
of Product Characteristics (SPC): intravenous infusion 
administered in 30 min.
For safety reasons, G- CSF administration has to be 
interrupted if the leucocyte count is ≥50 x 109/L.
Co-treatment
From the first day of each cycle, mannitol 18% is adminis-
tered intravenously, 125 mL two times per day for 5 days, 
in order to permeabilise the BBB35 and promote cells 
entry into the CNS.
Since filgrastim treatment may cause flu- like disorders, 
in order to maintain the blindness of the study, all patients 
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Table 2 Study flowchart
Evaluation
Visit
V1 V2 V3 V4 V5 V6 V7 V8 V9
Time (weeks)  0 4 12 24 36 48 60 72
Informed consents X                 
Medical history X                 
Physical examination X X X X X X X X X
Vital signs X X X X X X X X X
Blood chemistry X X X X X X X X X
ALS- FRS- R X X X X X X X X X
Neurological examination X     X X X X X X
MRC X     X X X X X X
Spirometry X X   X X X X     
McGill QoL Scale   X     X   X   X
ECAS X     X X X X     
Bone marrow aspirate X                 
Treatment X X   X X X       
Lumbar puncture X X     X         
DNA collection X                 
Concomitant therapies X X X X X X X     
Other procedures*   X X X X X X X X
  Screening Treatment Follow- up
  4 weeks max 48 weeks 24 weeks
*Include enteral or parenteral feeding (eg, percutaneous endoscopic gastrostomy) and/or respiratory support (non- invasive ventilation, 
tracheostomy, intubation).
ALS- FRS- R, Amyotrophic Lateral Sclerosis Functional Rating Scale- Revised; ECAS, Edinburgh cognitive and behavioral ALS screen; MRC, 
Scale for Testing Muscle Strength; QoL, quality of life.
receive prophylactic treatment with paracetamol 1000 mg 
intravenously for each day of the treatment cycle, plus 
other 1000 mg intravenously as needed for up to three 
times per day.
treatment scheme
From day 1 to day 4
 ► Mannitol 18% 125 mL at least 30 min before the first 
filgrastim/placebo infusion.
 ► First administration of filgrastim/placebo in 5% 
glucose solution by intravenous infusion over 30 min.
 ► Approximately 3 hours after the first infusion of 
filgrastim/placebo, administration of paracetamol 
1000 mg intravenously.
 ► At least 30 min before the second infusion of 
filgrastim/placebo, administration of mannitol 18% 
125 mL.
 ► 6 hours after the first infusion, second administration 
of filgrastim/placebo in 5% glucose solution by intra-
venous infusion over 30 min.
Day 5
Mannitol 18% 125 mL two times per day about 6 hours 
apart and paracetamol 1000 mg intravenously between 
the two mannitol infusions
Procedures and evaluations
Clinical assessments
The study flowchart is reported in table 2.
During the visit of screening before entering the study 
(V1), the patient must provide the report of the following 
tests, performed in the last 30 days: an ECG, a chest X- ray, 
an ultrasound scan of neck, with evaluation of nodal sites, 
abdomen, with spleen volume assessment, and inguinal 
region. These tests are repeated later only if clinically 
indicated.
Only at the screening, a bone marrow aspiration with 
morphological and cytogenetic evaluation and in vitro 
cultures is performed. AEs were assessed at each visit.
Evaluation of BMCs mobilisation into peripheral blood and CSF
Complete blood cell counts and determination of 
circulating CD34+ cells to evaluate dismissal of BMCs 
are performed daily throughout all the cycles of G- CSF 
administration (5 days) and at every visit before the infu-
sion. The evaluation of the presence of BMCs in the CSF 
is assessed with a lumbar tap at Day 4 of the first (V2) and 
of the third (V5) cycle of the G- CSF administration, and 
compared with a basal evaluation performed during the 
screening (V1).
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End-points
 ► Primary end- point (efficacy analysis): assessment of change 
in the rate of progression of total disability score (ALS- 
FRS- R Score) over the 72 weeks of the study (48 weeks 
of treatment + 24 weeks of follow- up) in a series of ALS 
patients compared with placebo, calculated as follows: 
ALS- FRS- R slope = [score ALS- FRS- R (time 0) − score 
ALS- FRS- R (time 72)]/72 Day 4.
 ► Secondary end- points (secondary efficacy analyses and safety 
and tolerability analyses) include:
 – Modification of progression rates of MRC Score, 
respiratory function (FVC) and QoL (measured 
with McGill QoL Questionnaire) during all the 
study, calculated with the same formula reported 
for ALS- FRS- R.
 – Time to death or tracheostomy (survival analysis) 
or use of non- invasive ventilation ≥18 hours/day.
 – Interruption of treatment due to disease progres-
sion or to an AE.
 – Safety and tolerability analysis: comparison be-
tween serious adverse event (SAE) in patients treat-
ed with drug and placebo.
statistical analysis
The statistical analysis plan includes descriptive statis-
tics for the assessment of the comparability of the two 
treatment groups and the safety of active treatment and 
placebo, and the use of ad- hoc statistical tests (univariable 
and multivariable) for the efficacy analysis.
Statistical analysis is performed in the following study 
populations:
 ► All randomised patients receiving at least one dose of 
the study medication (‘intention- to- treat population’) 
(primary analysis).
 ► Study completers: patients completing the 12- month 
observation period (secondary analysis).
 ► Study completers and compliers; patients completing 
the 12- month observation period and taking at least 
75% of assigned drug dose (secondary analysis).
The primary statistical analysis includes the evaluation 
of change in the rate of disease progression in the treat-
ment period (from T0 to T72) using the global score of 
the functional scale ALS- FRS- R, comparing the velocity 
averages in the two treatment groups. The analysis will 
be performed as intention- to- treat, including all patients 
recruited for the study and who have performed at least 
one course of treatment.
Patients leaving the study for any reason will not be 
replaced.
The secondary statistical analyses include the evalua-
tion of the change in the rate of progression of muscle 
strength (upper limbs MRC, lower limbs MRC, overall 
MRC), respiratory function (FVC) and the overall score 
of the McGill Scale (QoL).
A Student’s t- test is employed to compare the progres-
sion rate averages of the various parameters (slopes of the 
ALS- FRS- R, MRC, QoL Scores and FVC) between the two 
treatment groups.
For patients who do not complete the trial (leave the 
study before the 72 weeks provided by the protocol for 
death or withdrawal of consent), slopes are calculated 
using the last observation performed, before the exit from 
the study, divided by the number of weeks of observation.
Survival is assessed using the Kaplan- Meier method 
with death or tracheostomy as end- points and log- rank 
test. Cox’s proportional hazard model is employed to 
adjust for any unbalanced distribution among prognostic 
factors. Statistical significance is considered at a level of 
0.05 with two- tailed tests.
About end- points related to security, all patients under-
going at least one course of treatment are included in the 
safety analysis. Any alterations of vital signs or laboratory 
tests are detected during the course of the study. All data 
are tabulated including incidence and severity of AE.
sample size and study power
According to the data of our ALS centre, calculated on 
850 patients prospectively followed- up during the last 10 
years, the mean score of ALS- FRS- R shows a 11.3 points 
decrease with a SD of 8.2 points during the first year 
after the diagnosis (1 year of follow- up). With a two- sided 
alpha set at 0.05 and a power (beta) of 0.9, we can calcu-
late that in order to find a difference of 6.7 points in the 
ALS- FRS- R Score (ie, a reduction of 6.7 points in the ALS 
progression) we will need 38 patients in each arm (drug 
vs placebo). Secondary objectives are to investigate cyto-
kine/chemokine levels and NOX2 activity in the CSF and 
blood of patients before and after the treatment using 
multiplexed fluorescent bead- based immunoassay and 
oxidative burst assay. This will allow to implement the 
interesting data obtained from our preliminary studies 
which indicated significant and selective changes of 
specific cytokines in the CSF and serum of G- CSF treated 
patients showing a trend to slowing down the disease 
progression.
Pharmacovigilance
All centres participate in the pharmacovigilance 
programme.
The definitions of AEs, SAE, adverse reaction (AR), 
serious adverse reaction (SAR) and suspected unex-
pected serious adverse reaction (SUSAR) are those 
reported in the The Medicines for Human Use- Clinical 
Trials- Regulations (2004).
Criteria of seriousness for SAE, SAR and SUSAR
Any AE or AR that, irrespective of the dose, corresponds 
to one or more of the following criteria is considered 
serious:
 ► Has a fatal outcome.
 ► Endangers the life of the subject.
 ► Requires hospitalisation or prolongs the admission in 
progress.
 ► Involves severe or prolonged disability or incapacity.
 ► Involves a congenital anomaly or a birth defect.
 ► New diagnosis of cancer.
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Table 3 Adverse reactions reported in the summary of product characteristics of G- CSF
Systems/organs involved Adverse effect Frequency
Hemolymphopoietic system disorders Leucocytosis, thrombocytopenia Very common
Spleen disorders Uncommon
Metabolism and nutrition disorders High levels of alkaline phosphatase and lactate 
dehydrogenase
Common
Increase in serum glutamic- oxaloacetic 
transaminase, hyperuricemia
Uncommon
Nervous system disorders Headache Very common
Vascular disorders Capillary loss syndrome Uncommon
Musculoskeletal and connective tissue disorders Musculoskeletal pain Very common
Rheumatoid arthritis exacerbation Uncommon
General disorders and administration site conditions Serious allergic reaction Uncommon
Skin and subcutaneous tissue disorders Sweet syndrome, cutaneous vasculitis Uncommon
Notification and reporting responsibilities of AE, AR, SAE, SAR and 
SUSAR
AE (non- treatment- related) or AR (treatment- related) 
are any change in the patient’s clinical condition from 
baseline that is not due to the expected course of the 
disease and that has a potential clinical significance or 
any clinical event presented by the patient who is partic-
ipating in the study. It therefore includes lesions, toxic 
effects, hypersensitivity reactions, diseases not related 
to the study disorder, surgical interventions that occur 
during the study after the start of the treatment (V2−T0).
All AE and AR that occur in a patient or subject involved 
in a clinical trial must be collected and reported in the 
appropriate case report form (CRF).
All AE for which, in the opinion of the clinical trial 
investigator or promoter, there is a reasonable suspicion 
that a causal relationship may exist with an investigational 
medicinal product, are to be considered AR.
In compliance with what reported in the SPC, the events 
showed in table 3 are called reactions. Reactions defined 
as very common are not notified if their degree of toxicity 
is equal to or less than 3 (as per Common Terminology 
Criteria for Adverse Events V.5.0).
With regard to the management of reporting, appro-
priate standard operating procedures are shared with all 
participating centres. In particular, SAE and SAR must 
be reported by each PI to coordinating centre and to 
ethics committee (EC) and health management of the 
corresponding centre. SUSAR are inserted in the phar-
macovigilance system. The notification obligation related 
to the conduct of the study will cease with its closure.
Withdraw from the study
A subject may voluntarily choose to stop treatment or with-
draw consent to participate in the trial at any time. Also 
the investigator may suspend the treatment or exclude a 
patient from the study at his discretion in any moment. 
The withdrawal is to be considered from the moment 
of the informed consent sign and before the final visit 
completion. During the 48 weeks of treatment, failure 
of an entire course of treatment (4 days of filgrastim/
placebo administrations) leads to the exclusion from the 
study.
blind opening
The pharmacy of each participating centre is authorised 
to open the envelope to learn about the associated treat-
ment. The participant centre can only open the envelope 
in case of urgency or when the patient’s clinical condi-
tions require it. In any case, they provide to document the 
reasons for opening the blind, the person who performed 
the operation and the methods. This document must be 
sent immediately by email to the pharmacy of the coordi-
nating centre.
Early termination
Filgrastim treatment must be suspended in case of:
 ► Haematuria/proteinuria.
 ► Pregnancy.
 ► If the maximum spleen diameter is >14 cm (drug 
administration has, however, to be suspended in all 
patients in case of rapid and marked increase in the 
spleen, already detected at palpation).
 ► An AE/SAE or clinically significant condition assessed 
by the investigator as a significant and unacceptable 
risk for the subject.
Patients excluded or withdrawn from the study will still 
be subjected to a 24- week follow- up (two visits every 12 
weeks).
Conclusion of the study
The study will be considered concluded when the last 
randomised patient completes the last follow- up visit fore-
seen by the protocol and the related data will be included 
in the CRF.
regulatory requirements—promoter/researcher obligations
The steering committee of the study consists of the PI of 
each participating centre or one of its representatives.
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The protocol has been discussed and revised according 
to the suggestions of the data safety and monitoring 
board, consisting of three independent experts appointed 
by the promoter of the study, in particular a Professor of 
Neurology, a Professor of Haematology and a Professor of 
Pharmacology of the University of Turin.
This study is conducted in accordance with the Helsinki 
Declaration (Fortaleza, October 2013) and the Interna-
tional Council for Harmonisation of Technical Require-
ments for Pharmaceuticals for Human Use (ICH) E6 
guidelines. To this end, with the written approval of 
this protocol, the researchers agree to fully cooperate 
allowing access to authorised individuals to all documen-
tation, including hospital records (source documents).
Researchers must strictly adhere to the protocol. If 
necessary, a written amendment to the protocol will be 
prepared. The amendment will be approved and signed 
by the participating parties (Investigators and Promoters) 
according to defined procedures.
The investigators collect study data by entering them 
into the trial database through electronic CRF and are 
responsible for the accuracy of all data entered. The CRF 
must be available for review by designated representatives 
in case of monitoring visits. The researchers also allow 
representatives of regulatory bodies to review the data 
reported in the CRF and source documents, according to 
the laws and regulations in force.
The study will be monitored by a certified contract 
research organisation. The researchers make available all 
relevant material, including the source documents, for 
any inspection by the regulatory authorities (audit). The 
information is considered confidential.
The trial is insured for damages arising from the study 
and involving the subjects treated with the study drug 
according to the laws in force. Researchers receive all 
data concerning the insurance company and the policy 
number.
Any violation of the protocol will imply, on the side of 
the promoter, the suspension of the treatment of that 
patient and the study can be interrupted at any time by 
the promoter and/or the responsible researcher on the 
basis of new information regarding the treatment safety. 
Furthermore, the study can be interrupted if the treat-
ment should give clearly unsatisfactory results.
Patient and public involvement
Patients have not been involved in the drafting of the 
research protocol and will not be involved in study 
conduction or in the interpretation of the results. Patient 
associations will be invited to disseminate the trial, to 
allow patients to participate in it with maximum adher-
ence and to spread the results of the study.
EthICs And dIssEMInAtIon
The study protocol was approved by the EC of Città 
della Salute e della Scienza di Torino and by the ECs of 
participating centres based on the Helsinki declaration 
(Fortaleza, October 2013). Comitato Etico Interaziendale 
AOU Città della Salute e della Scienza di Torino – AO 
Ordine Mauriziano di Torino – ASL TO1, approval ID: 
CS/260 (signed on 1st July 2015).
All patients included in the study from each partici-
pating centre must personally sign the informed consent 
form approved by their EC, after receiving detailed infor-
mation on all aspects of the trial (see online supplemen-
tary file). The researcher must ensure anonymity by using 
an alphanumeric code for each subject.
No study procedure will be performed before the 
written informed consent has been provided.
The data of the study are property of the promoter. 
The results can be presented in scientific conferences or 
published in scientific journals. All publications are prop-
erty of the main investigators of all the centres involved in 
the study. After the trial completion, the project coordi-
nator will prepare a draft manuscript containing the final 
results of the study. The manuscript will be discussed and 
approved by all the primary investigators of the centres 
involved in the study. The publications will respect the 
privacy of the participating subjects.
dIsCussIon
G- CSF safety in humans has been demonstrated by the 
wide clinical use in the last 20 years in subjects with 
leukaemia and in health donors of bone marrow. Many 
observations suggest that G- CSF may affect the CNS and 
neural cells in particular. Therefore, we decided to use 
G- CSF to mobilise BMCs into the peripheral circulation 
in patients with ALS.
We have previously completed an open- blind phase I 
study ‘STEMALS’36 37 on 26 patients treated with G- CSF 
(subcutaneous injection) at the dose of 5 µg/kg two times 
per day for four consecutive days, with mannitol 18% 
intravenously, 125 mg, two times per day; the treatment 
was repeated four times, at 3- month interval. We demon-
strated that BMCs mobilisation was constant at each cycle, 
with a peak of some 40–50 x 109 leucocytes/L. G- CSF 
treatment was safe and feasible in the multicentre series 
of ALS patients.
Moreover, the treatment with G- CSF produced a signif-
icant reduction of proinflammatory cytokines MCP-1 and 
IL17 in CSF, and an increase of IP10 in serum, suggesting 
a central anti- inflammatory response induced by the drug. 
In this regard, it is of particular interest that the expres-
sion of IP10 is significantly reduced in lymphocytes of ALS 
patients with the C9ORF72 expansion compared with 
controls and non- C9ORF72 SLA patients. Furthermore, 
the levels of this cytokine in the CSF of ALS patients are 
inversely correlated with the progression of the disease, 
hypothesising a neuroprotective effect of IP10.20
The ROS- producing NOX2 enzyme plays a role in the 
development of neurological diseases. In our previous 
studies we verified its activity in blood of patients with 
ALS, Chronic Inflammatory Demyelinating Polyneu-
ropathy (CIDP) and Parkinson’s disease, in addition to 
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healthy volunteers, finding the strong role of NOX2 in 
modifying progression in ALS patients.38
Since NOX2 is responsible for the respiratory oxidative 
burst, the assessment of its activity in granulocytes before 
and after the treatment with drug/placebo may help us 
to determine if G- CSF can affect cellular oxidative status.
The most common adverse effects were flu- like symp-
toms, nausea and asthenia, reported by eight patients 
over the total course of 12 treatment cycles, and effec-
tively treated with acetaminophen (500 mg two times 
per day); the only serious adverse effects were a deep 
venous thrombosis requiring anticoagulation therapy for 
4 months in a case and transient hyperprolactinemia in 
another case (manifested by asthenia and decrease of 
libido).
The rate of progression of ALS, measured with ALS- 
FRS- R Score and respiratory function, decreased by 30% 
comparing the lead- in 4- month period and the 12 months 
of the study.
In the last years, some new trials with ALS patients 
treated with subcutaneous injections of G- CSF have been 
performed. Amirzagar et al39 have concluded that G- CSF 
is not a promising option for the treatment of ALS and 
it may accelerate disease progression in females, while 
Johannesen et al40 suggested that G- CSF treatment is 
feasible and safe and may exert beneficial effects.
In conclusion, these results prompt us to perform 
‘STEMALS- II’, a multicentre phase II randomised clinical 
trial to provide specific information on G- CSF intrave-
nous treatment on the course of ALS in a larger number 
of cases. Intravenous administration was chosen because 
it was less irregular, ensuring a more reliable dose of 
drug. A demonstration of a positive effect on the rate of 
disease progression will give ALS patients a new thera-
peutic opportunity to be used with riluzole. This will be 
very important result for a fatal disorder which currently 
has no effective therapies. Being G- CSF an already avail-
able and used drug, its translation to clinical use in ALS 
patients does not need extremely long times.
Moreover, the 12- month assessment of chemokines, 
cytokines and NOX2 activity, both in treated and non- 
treated (placebo) ALS patients, and its correlation with 
demographic and clinical parameters, will provide us a 
mass of biological data longitudinally collected, which 
could lead to important information on the trend of 
neuroinflammation in ALS.
The demonstration of specific patterns of neuroinflam-
mation markers could offer new possible targets of other 
drugs for the treatment of ALS, as well as new markers of 
disease progression to be used as surrogate markers in 
future trials on ALS patients.
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